Proven links between NAFLD and decreased bone mass include vitamin D insufficiency 96, the growth hormone/IGF-I axis 97, TNF-α 98, the receptor activator of NF-κB (RANK)/osteoprotegerin pathway 99, fetuin-A 100, osteopontin 101, and adiponectin 102. This evidence concerns the gene TNFRSF11A and metabolic dysfunction-associated steatotic liver disease.